The Brand Name ONCOCRISTIN-AQ Has Generic Salt :: Vincristine 

ONCOCRISTIN-AQ  Is From Company Sun Priced :: Rs. 46.79

ONCOCRISTIN-AQ have Vincristine is comes under Sub class Anti Neoplastic Agents of  Main Class Anti Neoplastic Agents

Main Medicine Class:: Anti Neoplastic Agents  Sub Medicine Class :: Anti Neoplastic Agents 

 Salt Name :  OR Generic Name Form Price : MRP /Probable Packing
Vincristine  INJ  Rs. 46.79  1ML
Brand Name Company / Manufacturers Strength Unit Price / 1ML
 ONCOCRISTIN-AQ  Sun  1MG/ML  1ML Rs. 46.79

Company  Brand Name  Salt Combination Main Medical Class Sub Medical Class
 From Sun :: ONCOCRISTIN-AQ  Vincristine  Anti Neoplastic Agents Anti Neoplastic Agents

Indications for Drugs ::

Acute lymphoblastic leukaemia; Acute myeloid leukaemia; AIDS-related Kaposi’s sarcoma; Brain tumours; Hodgkin’s disease; Neuroblastoma; Non-Hodgkin’s lymphoma; Small cell lung cancer; Wilm’s tumour

Drug Dose ::

Intravenous Acute lymphoblastic leukaemia, AIDS-related Kaposi’s sarcoma, Hodgkin’s disease, Neuroblastoma, Small cell lung cancer, Wilm’s tumour, Brain tumours, Non-Hodgkin’s lymphoma, Acute myeloid leukaemia Adult: Usual recommended dosage: 1.4-1.5 mg/m2 once wkly. Max: 2 mg wkly. Subsequent doses may be modified based on clinical and haematological responses and tolerance of the patient. May be used in combination with other drugs. Prescribers should consult published protocols for the dosage, method and sequence of admin. Child: Usual recommended dosage: 1.5-2 mg/m2 once wkly; for patients ?10 kg: Initiate at 0.05 mg/kg once wkly. Subsequent doses may be modified based on clinical and haematological responses and tolerance of the patient. May be used in combination with other drugs. Prescribers should consult published protocols for the dosage, method and sequence of admin. Hepatic impairment: Dose adjustment may be needed. Serum bilirubin >3 mg/100ml: Reduce dose by 50%.

Contraindication ::

Patients with demyelinating form of Charcot-Marie-Tooth syndrome. Pregnancy and lactation. Intrathecal admin (may be fatal). Patients receiving radiation therapy through ports which include liver.

Drug Precautions ::

Elderly. Preexisting pulmonary dysfunction or neuromuscular disease; leucopenia or a complicating infection; impaired liver function; obstructive jaundice. Routine prophylactic laxative needed to ensure regular bowel movement. Discontinue immediately if extravasation occurs, and inj any remaining drug into another vein, followed by local Inj of hyaluronidase and topical heat application to the affected area to aid in drug removal and reduce discomfort. Discontinue in patients who develop progressive dyspnea. CBC to be checked before each dose admin. Frequent monitoring of uric acid during first 3-4 wk of treatment and watch out for uric acid nephropathy.

Drug Side Effects ::

Dose limiting neurotoxicity (e.g. motor function impairment, gait abnormalities), hyperuricaemia, bronchospasm, azospermia, amenorrhoea, alopoecia, leucopenia, urinary dysfunction, abdominal cramps, vomiting, diarrhoea, severe constipation, paralytic ileus, convulsions, hypertension, orthostatic hypotension, ptosis, hoarseness, optic neuropathies, hallucinations, blindness, neurological deafness, difficulty in walking, syndrome of inappropriate ADH secretion. Potentially Fatal: Myelosuppression.

Pregnancy category ::
Pregnancy category


Drug Mode of Action ::  

Vincristine arrests cell division at the metaphase stage by inhibiting microtubule formation in the mitotic spindle.

Drug Interactions ::

Decreased digoxin (tablets) and verapamil absorption with antineoplastic regimens. Increased etoposide serum levels with vincristine. Increased toxicity when ganciclovir given with, immediately before or after vincristine. Reduced vincristine metabolism with miconazole. Increased neurotoxicity with isoniazid, itraconazole, voriconazole, posaconazole and nifedipine. Decreased immune response when used concurrently with vaccines. Increased myelotoxicity with zidovudine. Increased risk of thromboembolic complications with tamoxifen. Increased risk of ototoxicity with ototoxic drugs (e.g. platinum-containing antineoplastic agents). Possible risk of earlier onset and/or increased severity of adverse effects with macrolides. Possible increase in vincristine levels with aprepitant. Possible decrease in antiepileptic levels with vincristine, monitor serum antiepileptic levels and effectiveness of chemotherapy. Potentially Fatal: Increased risk of bronchospasm with mitomycin C. Reduced vincristine clearance and increased toxicity with asparaginase, minimise toxicity by giving vincristine 12-24 hr before L-asparaginase admin.


Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.


One of the 1st in India.High Quality Generic Medicine Portal Android Application for Online Oreder & Information.

For More Join Our Membership and Get Additional 25% off on Meds, also get MLM Benefits to get a permanent earning source.

Join Membership How to Search Medicine
Android App

We would like to keep you updated with special notifications.